A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: Efficacy and safety analysis (BOLD-100-001).
- Jennifer Spratlin
- , Sun Young Rha
- , Grainne M. O'Kane
- , Do Youn Oh
- , Elena Elimova
- , Rachel Anne Goodwin
- , Seung Tae Kim
- , Dong Hoe Koo
- , E. Russell McAllister
- , Michelle Jones
- , Malcolm Snow
- , Yasmin Lemmerick
- , Gonzalo Spera
- , Jim Pankovich
- Cross Cancer Institute
- Yonsei University
- Trinity College Dublin
- Seoul National University
- Princess Margaret Cancer Centre
- University of Ottawa
- Kangbuk Samsung Hospital
- Bold Therapeutics Inc.
- Inc.
- Canada
- Translational Research in Oncology
Research output: Contribution to journal › Article › peer-review
2
Link opens in a new tab
Scopus
citations